Tesamorelin is approved for one narrow use: reducing excess abdominal fat in certain people with HIV. It has other human studies too, but that does not make it a general weight-loss, fatty-liver, memory or anti-ageing treatment.
Still uncertain: Benefits outside the studied HIV populations, including general obesity, general fatty-liver disease and cognitive enhancement.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
GHRH analogue peptide
Entity type
Peptide analogue / modified peptide
Research focus
Excess abdominal visceral fat in adults with HIV and lipodystrophy
Human evidence
Tesamorelin has strong evidence for its narrow HIV-associated abdominal-fat indication. A randomized HIV/NAFLD study also reduced liver fat substantially, while a small 2025 Phase II cognitive trial did not show significant between-group cognitive benefit.
Regulatory status
FDA-licensed Egrifta formulations are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy; not a general weight-loss approval.
Main limitations
General obesity treatment, general NAFLD therapy or cognitive enhancement outside studied HIV populations.
Safety
Glucose intolerance, edema, joint symptoms and IGF-1 elevation are among important label considerations.
Evidence reviewed
2026-09-18
i
Tesamorelin has strong evidence for its narrow HIV-associated abdominal-fat indication. A randomized HIV/NAFLD study also reduced liver fat substantially, while a small 2025 Phase II cognitive trial did not show significant between-group cognitive benefit.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Tesamorelin reduced liver fat by an absolute 4.1 percentage points versus placebo, about a 37% relative reduction; 35% versus 4% reached hepatic fat fraction <5%.
Tesamorelin and neurocognitive impairment in people with HIV and abdominal obesity
2025 · Randomized open-label Phase II trial · n=73
Within-group cognitive score improved numerically with tesamorelin, but the between-group difference was not significant (P=0.673); waist circumference declined more with tesamorelin.
Glucose intolerance, edema, joint symptoms and IGF-1 elevation are among important label considerations.
Raises IGF-I and can affect glucose; labelled use includes monitoring and contraindications. Current EGRIFTA formulations have formulation-specific dosing/reconstitution and are not automatically interchangeable.
Technical details
Mechanism / biologyGHRH receptor agonist increases endogenous GH and IGF-1.
Route / formulation boundaryResearch-market tesamorelin is not automatically equivalent to authorised Egrifta products.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published Phase 3 human regimen. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
3outcome records
9linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
